| Description | Fluasterone, an NF-κB activation inhibitor, is used potentially for the treatment of metabolic syndrome. |
| Synonyms | HE 2500, HE-2500, HE2500 |
| molecular weight | 290.42 |
| Molecular formula | C19H27FO |
| CAS | 112859-71-9 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Burgess JP, Green JS, Hill JM, Zhan Q, Lindeblad M, Lyubimov A, Kapetanovic IM, Schwartz A, Thomas BF. Identification of [14C]fluasterone metabolites in urine and feces collected from dogs after subcutaneous and oral administration of [14C]fluasterone. Drug Metab Dispos. 2009 May;37(5):1089-97. doi: 10.1124/dmd.108.023614. PubMed PMID: 19196848; PubMed Central PMCID: PMC2683393. 2. Lindeblad MO, Bauer KS, Zakharov AD, Hill JM, Green JS, Thomas BF, Schwartz A, Kapetanovic IM, Lyubimov A. Pharmacokinetic and tissue distribution study of [14C]fluasterone in male Beagle dogs following intravenous, oral and subcutaneous dosing routes. Chem Biol Interact. 2010 Jan 27;183(2):317-26. doi: 10.1016/j.cbi.2009.10.004. PubMed PMID: 19836365. 3. McCormick DL, Johnson WD, Kozub NM, Rao KV, Lubet RA, Steele VE, Bosland MC. Chemoprevention of rat prostate carcinogenesis by dietary 16alpha-fluoro-5-androsten-17-one (fluasterone), a minimally androgenic analog of dehydroepiandrosterone. Carcinogenesis. 2007 Feb;28(2):398-403. PubMed PMID: 16952912. 4. He Y, Li P, Yalkowsky SH. Solubilization of Fluasterone in cosolvent/cyclodextrin combinations. Int J Pharm. 2003 Oct 2;264(1-2):25-34. PubMed PMID: 12972333. |